Sue Yom
Expertise in
28
conditions

Dr. Sue Yom

Radiation Oncology | Otolaryngology
1825 Fourth Street, Third Floor, 
San Francisco, CA 
On Staff At
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Expertise in
28
conditions
1825 Fourth Street, Third Floor, 
San Francisco, CA 

Overview

Dr. Sue Yom is an expert in the radiation treatment and management of head, neck and lung cancers. In her research, Yom studies chemoradiation (a combination of chemotherapy and radiation) for these cancers. She also investigates image-guided radiation therapy and ways to reduce toxic effects using focused radiation techniques, emerging biological agents and radiation protectants. Yom earned her medical and doctoral degrees at the University of Pennsylvania. She completed a residency in radiation oncology at the MD Anderson Cancer Center. Yom has received numerous awards recognizing her commitment to patient care and patient-oriented research.

Dr. Yom is highly rated in 28 conditions, according to our data. Her top areas of expertise are Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Merkel Cell Carcinoma, and Olfactory Neuroblastoma.

Her clinical research consists of co-authoring 302 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

University Of Pennsylvania School Of Medicine, MD

Residency

University of Texas Health Science Ctr - Houston, Radiation Oncology

Specialties

Radiation Oncology
Otolaryngology

Licenses

Radiology in TX

Board Certifications

American Board Of Radiology, Radiation Oncology

Hospital Affiliations

Zuckerberg San Francisco General Hosp & Trauma Ctr
Ucsf Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Chinese Community Health
  • HMO
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Contra Costa Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PacificSource
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Melanoma & Skin Cancer Center
1825 Fourth Street, Third Floor, San Francisco, CA 94158
Other Locations
Melanoma & Skin Cancer Center
1600 Divisadero St., Third Floor, San Francisco, CA 94115
Radiation Oncology at Mount Zion
1600 Divisadero St., Basement Level, San Francisco, CA 94115
Radiation Oncology at Mission Bay
1825 Fourth St., First Floor, Room L1101, San Francisco, CA 94158

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC
A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC
Enrollment Status: Recruiting
Publish Date: January 16, 2026
Intervention Type: Drug, Radiation
Study Drugs: NBTXR3, Cetuximab
Study Phase: Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
Nivolumab in Combination With Chemoradiation for Patients With Stage II-IVB Nasopharyngeal Carcinoma, A Phase II Study With Correlative Biomarkers
Nivolumab in Combination With Chemoradiation for Patients With Stage II-IVB Nasopharyngeal Carcinoma, A Phase II Study With Correlative Biomarkers
Enrollment Status: Completed
Publish Date: January 12, 2026
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Cisplatin
Study Phase: Phase 2
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Intervention Type: Other, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 31, 2025
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Cisplatin, Carboplatin
Study Phase: Phase 2
PembroX: Enhancing the Immunogenicity of Non-Small Cell Lung Cancer With Pembrolizumab +/- Stereotactic Radiotherapy Delivered in the Preoperative Window, A Randomized Phase II Study With Correlative Biomarkers
PembroX: Enhancing the Immunogenicity of Non-Small Cell Lung Cancer With Pembrolizumab +/- Stereotactic Radiotherapy Delivered in the Preoperative Window, A Randomized Phase II Study With Correlative Biomarkers
Enrollment Status: Completed
Publish Date: October 23, 2024
Intervention Type: Radiation, Procedure, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 1 / Phase 2 Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer
A Phase 1 / Phase 2 Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer
Enrollment Status: Completed
Publish Date: March 15, 2023
Intervention Type: Drug, Radiation
Study Drugs: BMX-001, Cisplatin
Study Phase: Phase 1/Phase 2
A Phase II Study of Radiation Therapy and Vismodegib, for the Treatment of Locally Advanced Basal Cell Carcinoma of the Head and Neck
A Phase II Study of Radiation Therapy and Vismodegib, for the Treatment of Locally Advanced Basal Cell Carcinoma of the Head and Neck
Enrollment Status: Completed
Publish Date: May 03, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 2
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: August 05, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 2
View 10 Less Clinical Trials

302 Total Publications

Consensus Co-Expression Analysis Identifies A Common Set Of Co-Expressed Genes Associated With Diabetic Peripheral Neuropathy And Chemotherapy-Induced Peripheral Neuropathy.
Consensus Co-Expression Analysis Identifies A Common Set Of Co-Expressed Genes Associated With Diabetic Peripheral Neuropathy And Chemotherapy-Induced Peripheral Neuropathy.
Journal: bioRxiv : the preprint server for biology
Published: December 03, 2025
Similar Doctors
Expertise in
22
conditions
Dr. David R. Raleigh
Radiation Oncology
Expertise in
22
conditions
Dr. David R. Raleigh
Radiation Oncology

University Of California San Francisco

400 Parnassus Ave, Mcb300, 
San Francisco, CA 
 (1.7 miles away)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Raleigh is a Radiation Oncologist in San Francisco, California. Dr. Raleigh is highly rated in 22 conditions, according to our data. His top areas of expertise are Meningioma, Pineocytoma, Brain Tumor, and Gliomatosis Cerebri.

Expertise in
15
conditions
Dr. Richard T. Hoppe
Radiation Oncology
Expertise in
15
conditions
Dr. Richard T. Hoppe
Radiation Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (28.3 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances

Richard Hoppe is a Radiation Oncologist in Stanford, California. Dr. Hoppe is highly rated in 15 conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, Mycosis Fungoides, Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), and Cutaneous T-Cell Lymphoma (CTCL).

Expertise in
38
conditions
Dr. Steve E. Braunstein
Radiation Oncology
Expertise in
38
conditions
Dr. Steve E. Braunstein
Radiation Oncology

University Of California San Francisco

505 Parnassus Ave, 
San Francisco, CA 
 (1.8 miles away)
415-476-1000
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Steve Braunstein is a Radiation Oncologist in San Francisco, California. Dr. Braunstein has been practicing medicine for over 17 years is highly rated in 38 conditions, according to our data. His top areas of expertise are Meningioma, Brain Tumor, Posterior Fossa Tumor, Gamma Knife Radiosurgery, and Osteotomy.

Frequently Asked Questions about Dr. Sue Yom

How do I make an appointment with Dr. Sue Yom?

You can book an appointment with Dr. Sue Yom by calling their office at 415-353-9900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sue Yom a top-rated expert for Nasopharyngeal Carcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sue Yom is classified as an Elite expert for Nasopharyngeal Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sue Yom specialize in?

While Dr. Sue Yom is a Radiation Oncology, they have specific expertise in Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), and Merkel Cell Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Sue Yom participate in research or clinical trials?

Yes. Dr. Sue Yom has published 302 articles and abstracts on conditions like Nasopharyngeal Carcinoma. You can view a list of Dr. Sue Yom's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sue Yom accept my insurance?

Dr. Sue Yom accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 415-353-9900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Yom's expertise for a condition
ConditionClose
View All 14 Distinguished Conditions
View All 13 Advanced Conditions
View All 40 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile